Calithera Biosciences, Inc
CALA
CALA was delisted on the 1st of February, 2023.
28 hedge funds and large institutions have $4.44M invested in Calithera Biosciences, Inc in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 32 closing their positions.
48% less funds holding
Funds holding: 54 → 28 (-26)
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
75% less capital invested
Capital invested by funds: $17.9M → $4.44M (-$13.5M)
81% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$261K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$67.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$54.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$47.2K |
| 5 |
VF
Virtu Financial
New York
|
+$46.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$539K |
| 2 |
Two Sigma Advisers
New York
|
-$502K |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$404K |
| 4 |
EAM
Empery Asset Management
New York
|
-$313K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$304K |
CALA Hedge Fund Activity: Q2 2022 in Review
28 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q2 2022, worth a combined $4.44M — down 75% from $17.9M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of CALA and 6 opened new positions — a net loss of 26 holders — while 14 trimmed existing stakes and 7 added.
The largest buyer was Acadian Asset Management, adding an estimated $261K. The largest seller was Primecap Management, cutting an estimated $539K.
- 28 institutional investors held Calithera Biosciences, Inc (CALA) as of Q2 2022, down from 54 in Q1 2022.
- Funds reported $4.44M of Calithera Biosciences, Inc stock for Q2 2022, down 75% quarter-over-quarter.
- 6 funds opened new Calithera Biosciences, Inc positions in Q2 2022 and 32 closed out, a net change of -26 holders.
- The largest Calithera Biosciences, Inc buyer in Q2 2022 was Acadian Asset Management, an estimated $261K added.
- The largest Calithera Biosciences, Inc seller in Q2 2022 was Primecap Management, an estimated $539K sold.
Based on aggregated 13F filings for Q2 2022.